BRPI0906722A2 - Métodos e composições usando polipeptídeos de fusão klotho-fgf - Google Patents
Métodos e composições usando polipeptídeos de fusão klotho-fgfInfo
- Publication number
- BRPI0906722A2 BRPI0906722A2 BRPI0906722-1A BRPI0906722A BRPI0906722A2 BR PI0906722 A2 BRPI0906722 A2 BR PI0906722A2 BR PI0906722 A BRPI0906722 A BR PI0906722A BR PI0906722 A2 BRPI0906722 A2 BR PI0906722A2
- Authority
- BR
- Brazil
- Prior art keywords
- klotho
- compositions
- methods
- fusion polypeptides
- fgf fusion
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6301508P | 2008-01-28 | 2008-01-28 | |
PCT/EP2009/050850 WO2009095372A1 (en) | 2008-01-28 | 2009-01-26 | Methods and compositions using klotho-fgf fusion polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0906722A2 true BRPI0906722A2 (pt) | 2015-07-07 |
Family
ID=40492768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906722-1A BRPI0906722A2 (pt) | 2008-01-28 | 2009-01-26 | Métodos e composições usando polipeptídeos de fusão klotho-fgf |
Country Status (21)
Country | Link |
---|---|
US (2) | US8481031B2 (pt) |
EP (1) | EP2247614B1 (pt) |
JP (1) | JP5627469B2 (pt) |
KR (1) | KR20100118126A (pt) |
CN (1) | CN102015760B (pt) |
AR (1) | AR070690A1 (pt) |
AU (1) | AU2009209696B2 (pt) |
BR (1) | BRPI0906722A2 (pt) |
CA (2) | CA2712634C (pt) |
CL (1) | CL2009000166A1 (pt) |
CO (1) | CO6300826A2 (pt) |
CR (1) | CR11580A (pt) |
EA (1) | EA201001204A1 (pt) |
EC (1) | ECSP10010372A (pt) |
ES (1) | ES2479417T3 (pt) |
IL (1) | IL207161A0 (pt) |
MA (1) | MA32031B1 (pt) |
MX (1) | MX2010008206A (pt) |
PE (1) | PE20091405A1 (pt) |
TW (1) | TW200936156A (pt) |
WO (1) | WO2009095372A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420088B2 (en) * | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
NZ596037A (en) * | 2009-05-05 | 2013-10-25 | Amgen Inc | Fgf21 mutants and uses thereof |
EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
WO2010148142A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
US8535912B2 (en) * | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
EP2506861A1 (en) * | 2009-12-02 | 2012-10-10 | Amgen Inc. | Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
JP2013514366A (ja) | 2009-12-16 | 2013-04-25 | イーライ リリー アンド カンパニー | 可溶性α−KLOTHOの治療的使用 |
EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
WO2011144756A1 (en) * | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
HUE031036T2 (en) * | 2010-06-25 | 2017-06-28 | Shire Human Genetic Therapies | Therapeutic drug delivery to the central nervous system |
CN102465182A (zh) * | 2010-10-29 | 2012-05-23 | 株式会社爱茉莉太平洋 | 检测皮肤活性物质的检测试剂盒和检测皮肤活性物质的方法 |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
WO2013027191A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
TWI478002B (zh) * | 2012-02-09 | 2015-03-21 | Univ Nat Sun Yat Sen | 一種篩選治療或預防帕金森氏症及其併發症之候選藥物的方法 |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
NZ630484A (en) | 2012-11-28 | 2017-04-28 | Ngm Biopharmaceuticals Inc | Compositions and methods for treatment of metabolic disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
JP6403685B2 (ja) * | 2012-12-27 | 2018-10-17 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 胆汁酸ホメオスタシス調整並びに胆汁酸障害及び疾患の治療の方法 |
WO2015060430A1 (ja) | 2013-10-24 | 2015-04-30 | 地方独立行政法人東京都健康長寿医療センター | 筋幹細胞又は筋芽細胞、及びそれを用いた代謝変換に関与する物質のスクリーニング方法、並びにスクリーニング方法によって得られた物質を含む医薬組成物 |
AU2014342630B2 (en) | 2013-10-28 | 2020-11-05 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
ES2808340T3 (es) | 2014-01-24 | 2021-02-26 | Ngm Biopharmaceuticals Inc | Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos |
US10464979B2 (en) | 2014-03-28 | 2019-11-05 | New York University | FGF23 c-tail fusion proteins |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
AU2015356643B2 (en) * | 2014-12-04 | 2019-01-24 | Novartis Ag | Methods and compositions using Klotho variant polypeptides |
CN105838661B (zh) * | 2014-12-30 | 2020-11-10 | 深圳市第二人民医院 | Klotho基因编辑在异种肾脏移植中的应用 |
CN107405382A (zh) * | 2015-02-06 | 2017-11-28 | 加利福尼亚大学董事会 | 用于改善认知的方法和组合物 |
US20180037868A1 (en) * | 2015-02-27 | 2018-02-08 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cell expressing klotho |
US11491115B2 (en) * | 2015-07-09 | 2022-11-08 | The Board Of Regents Of The University Of Texas System | Nanoparticles containing extracellular matrix for drug delivery |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
CA3082794A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals Inc. | Methods for treatment of bile acid-related disorders |
AU2017272349B2 (en) * | 2016-06-02 | 2022-12-01 | Klotho Therapeutics, Inc. | Therapeutic recombinant klotho proteins and compositions and methods involving the same |
EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
MX2019005687A (es) * | 2016-11-22 | 2019-09-05 | Klotho Therapeutics Inc | Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas. |
CA3069143A1 (en) | 2017-07-06 | 2019-01-10 | Yale University | Compositions and methods for treating or preventing endocrine fgf-linked diseases |
AU2018378802B2 (en) * | 2017-12-06 | 2024-08-15 | Klotho Therapeutics, Inc. | Products and methods for assessing and increasing Klotho protein levels |
CA3085322A1 (en) * | 2017-12-13 | 2019-06-20 | Yale University | Compositions and methods for treating or preventing endocrine fgf23-linked diseases |
CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
CN109722480B (zh) * | 2018-05-17 | 2022-04-26 | 上海交通大学 | 一种非小细胞肺癌检测试剂盒及其应用 |
US11969460B2 (en) | 2018-06-08 | 2024-04-30 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
US11891615B2 (en) | 2020-06-10 | 2024-02-06 | Gail Marion Humble | Process to produce Klotho protein in vitro |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406A (en) | 1849-05-01 | Artificial teeth | ||
US853A (en) | 1838-07-24 | Jesse reed | ||
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5266561A (en) | 1988-01-11 | 1993-11-30 | Amylin Pharmaceuticals, Inc. | Treatment of type 2 diabetes mellitus |
WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
WO1991019810A1 (en) | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5541094A (en) | 1992-09-25 | 1996-07-30 | E. I. Du Pont De Nemours And Company | Glyoxylic acid/aminomethylphosphonic acid mixtures prepared using a microbial transformant |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
US6187992B1 (en) | 1994-12-05 | 2001-02-13 | Merck & Co., Inc. | Transgenic mouse having a disrupted amyloid precursor protein gene |
JP2000507912A (ja) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | 作用剤の徐放性組成物 |
US6194177B1 (en) | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
EP0906090A1 (en) | 1996-03-15 | 1999-04-07 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
AU739057B2 (en) | 1996-12-26 | 2001-10-04 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Novel polypeptide, novel DNA, and novel antibody |
US6127598A (en) | 1997-07-25 | 2000-10-03 | The Regents Of The University Of California | NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
US6518069B1 (en) | 1999-04-22 | 2003-02-11 | Liposcience, Inc. | Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders |
US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
US20020082205A1 (en) | 2000-03-08 | 2002-06-27 | Nobuyuki Itoh | Human FGF-23 gene and gene expression products |
DE60141582D1 (de) | 2000-07-19 | 2010-04-29 | Advanced Res & Tech Inst | Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung |
US20030129686A1 (en) | 2001-01-30 | 2003-07-10 | Glass David J. | Novel nucleic acid and polypeptide molecules |
US7588757B2 (en) | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
JP2006240990A (ja) * | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途 |
CA2545539A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
JP2006158339A (ja) * | 2004-12-09 | 2006-06-22 | Kyoto Univ | βKlotho遺伝子、Cyp7a1遺伝子、及びそれらの利用 |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
-
2009
- 2009-01-22 TW TW098102662A patent/TW200936156A/zh unknown
- 2009-01-26 MX MX2010008206A patent/MX2010008206A/es active IP Right Grant
- 2009-01-26 EA EA201001204A patent/EA201001204A1/ru unknown
- 2009-01-26 CA CA2712634A patent/CA2712634C/en not_active Expired - Fee Related
- 2009-01-26 JP JP2010543520A patent/JP5627469B2/ja not_active Expired - Fee Related
- 2009-01-26 AU AU2009209696A patent/AU2009209696B2/en not_active Ceased
- 2009-01-26 ES ES09706624.5T patent/ES2479417T3/es active Active
- 2009-01-26 KR KR1020107019047A patent/KR20100118126A/ko not_active Application Discontinuation
- 2009-01-26 BR BRPI0906722-1A patent/BRPI0906722A2/pt not_active IP Right Cessation
- 2009-01-26 WO PCT/EP2009/050850 patent/WO2009095372A1/en active Application Filing
- 2009-01-26 CA CA2854933A patent/CA2854933A1/en not_active Abandoned
- 2009-01-26 CN CN200980111072.0A patent/CN102015760B/zh not_active Expired - Fee Related
- 2009-01-26 EP EP09706624.5A patent/EP2247614B1/en active Active
- 2009-01-27 PE PE2009000108A patent/PE20091405A1/es not_active Application Discontinuation
- 2009-01-27 AR ARP090100247A patent/AR070690A1/es unknown
- 2009-01-27 CL CL2009000166A patent/CL2009000166A1/es unknown
- 2009-01-28 US US12/360,970 patent/US8481031B2/en not_active Expired - Fee Related
-
2010
- 2010-07-19 MA MA33039A patent/MA32031B1/fr unknown
- 2010-07-21 CR CR11580A patent/CR11580A/es not_active Application Discontinuation
- 2010-07-22 IL IL207161A patent/IL207161A0/en unknown
- 2010-07-28 EC EC2010010372A patent/ECSP10010372A/es unknown
- 2010-07-28 CO CO10092102A patent/CO6300826A2/es not_active Application Discontinuation
-
2013
- 2013-05-29 US US13/904,574 patent/US9458209B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2479417T3 (es) | 2014-07-24 |
CO6300826A2 (es) | 2011-07-21 |
KR20100118126A (ko) | 2010-11-04 |
US8481031B2 (en) | 2013-07-09 |
US20090192087A1 (en) | 2009-07-30 |
CA2712634A1 (en) | 2009-08-06 |
PE20091405A1 (es) | 2009-10-07 |
MX2010008206A (es) | 2010-08-10 |
CL2009000166A1 (es) | 2010-12-24 |
IL207161A0 (en) | 2010-12-30 |
CN102015760B (zh) | 2014-06-11 |
MA32031B1 (fr) | 2011-01-03 |
CA2712634C (en) | 2014-09-16 |
EA201001204A1 (ru) | 2011-02-28 |
ECSP10010372A (es) | 2010-08-31 |
CN102015760A (zh) | 2011-04-13 |
US9458209B2 (en) | 2016-10-04 |
AR070690A1 (es) | 2010-04-28 |
JP5627469B2 (ja) | 2014-11-19 |
TW200936156A (en) | 2009-09-01 |
EP2247614A1 (en) | 2010-11-10 |
WO2009095372A1 (en) | 2009-08-06 |
AU2009209696A1 (en) | 2009-08-06 |
AU2009209696B2 (en) | 2012-04-19 |
CR11580A (es) | 2010-10-05 |
US20130324458A1 (en) | 2013-12-05 |
CA2854933A1 (en) | 2009-08-06 |
JP2011510620A (ja) | 2011-04-07 |
EP2247614B1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0906722A2 (pt) | Métodos e composições usando polipeptídeos de fusão klotho-fgf | |
BRPI0920284A2 (pt) | composição e método | |
BRPI0922084A2 (pt) | Composições e métodos compreendendo variantes de serina protease | |
BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
HK1206421A1 (en) | Anti-cxcr1 compositions and methods cxcr1 | |
DE602008002756D1 (de) | Bauzusammensetzung | |
BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
BRPI0906749A2 (pt) | Composição | |
PT2529016T (pt) | Métodos e composições utilizando polipéptidos de fusão fgf23 | |
BRPI0913625A2 (pt) | articulação esférica | |
BRPI0913808A2 (pt) | composição | |
ATE524493T1 (de) | Exendin-fusionsproteine | |
DK2356298T3 (da) | Kunstigt surfanlæg | |
DK3118221T3 (da) | Proteiner | |
IL207096A0 (en) | Modified leptin polypeptides and their uses | |
BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
DK2257618T3 (da) | Fremstilling af glykosylerede polypeptider i mikroalger | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
BRPI0917231A2 (pt) | composição | |
FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
DK2346679T3 (da) | Forbedrede kompositmaterialer | |
AT8372U3 (de) | Desmopressin umfassende zusammensetzung | |
DK2334596T3 (da) | Ferriphosphatbaseret sammensætning og anvendelse heraf | |
BRPI0918579A2 (pt) | composição de gel tensoativa | |
DK2262525T3 (da) | Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |